PNEUMOCYSTIC PNEUMONIA IN RHEUMATIC DISEASES: CURRENT ISSUES IN PROPHYLAXIS
https://doi.org/10.21518/2079-701X-2017-20-144-150
Abstract
In the current context, immunosuppressive therapy of systemic rheumatic diseases (RD) is becoming more widespread. At the same time, the active use of immunosuppressors including genetically engineered biological preparations is accompanied by an increase in opportunistic infections. The latter include pneumocystic pneumonia (PPn), which is a serious complication with significant mortality in patients with RD. However, given the heterogeneous data on the risks of specific RH and some or other immunosuppressive therapy, the development of a evidence-based comprehensive guide on the prevention of PPn in rheumatology is currently not possible. Specific guidelines for practical physicians can serve as algorithms of PPn prevention published by different authors, which are sure to be further followed-up (or processed) as new data are accumulated within the framework of the problem under consideration.
About the Author
M. S. Eliseev
Nasonova Research Institute of Reumatology.
Russian Federation
Russian Federation
PhD in medicine.
Moscow.
References
1. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научнопрактич. ревматол., 2004; 1: 5-7.
2. Елисеев М.С. Алгоритм диагностики и лечения подагры. РМЖ, 2015, 23(7): 410-414.
3. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum, 2004, 51(3): 321-5.
4. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 2016, 0: 1–14.
5. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis, 2012, 71: 1765-1770.
6. Kuo CF, Grainge MJ, Mallen C et al. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA, 2014, 312(24): 2684-6.
7. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford), 2007, 46: 1372-4.
8. Елисеев МС. Подагра. Ревматология. Клиничес кие российские рекомендации. М.: Геотар, 2017: 253-264.
9. Bose B, Badve SV, Hiremath SS et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant, 2014, 29: 406-413.
10. Krishnan E, Svendsen K, Neaton JD et al. Longterm cardiovascular mortality among middle aged men with gout. Arch Intern Med, 2008, 168: 1104-1110.
11. Higgins P, Dawson J, Lees KR et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and metaanalysis. Cardiovasc Ther, 2012, 30: 217-226.
12. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: asystematic review and meta-analysis. J Clin Hypertens (Greenwich), 2013, 15: 435-442.
13. Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив, 2015, 87(5): 10-15.
14. Chan EC, House ME, Petrie KJ et al. Complementary and alternative medicine use in patients with gout. The longitudinal observational study. J Clin Rheumatol, 2013, 20: 16-20.
15. Neogi T. Clinical practice. Gout. N. Engl. J. Med., 2011, 364: 443-52.
16. Eminaga F, Le-Carratt, Jones A, Abhishek A. Does the initiation. of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int, 2016, 36: 1747-52.
17. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: Analysis from managed care data. J. Clin. Rheumatol., 2006, 12(2): 61-65.
18. Silva L, Miguel ED, Peiteado D et al. Compliance in gout patients. Acta Reumatol. Port., 2010, 35(5): 466-74.
19. Khanna D, Fitzgerald J, Khanna P et al. 2012 American College of Rheumatology Guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), 2012, 64: 1431-1446.
20. Stamp L, Merriman T, Barclay M et al. Impaired response or insufficient dosage? Examining the potential causes of ‘inadequate response’ to allopurinol in the treatment of gout. Semin Arthritis Rheum, 2014, 44: 170-174.
21. Ryu H, Song R, Kim H et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol, 2013, 53: 211–216.
22. Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimi zing the risk. Nat Rev Rheum. 2016, 12: 235-42.
23. Stamp LK, Chapman PT, Barclay ML et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis, 2017, 0: 1-7.
24. Stamp L, Taylor W, Jones P et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum, 2012, 64: 25292536.
25. Swan S, Khosravan R, Mauer MD et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX67), a novel non-purine, selective inhibitor of xanthine oxidase. Arthr Rheum, 2003, 48(Suppl. 9): 529.
26. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res, 2014, 37(10): 919-25.
27. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med, 2013, 125(1): 106-14.
28. Sircar D, Chatterjee S, Waikhom R et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis, 2015, 66(6): 945-50.
29. Echteld IA, Durme C, Falzon L et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheum. Suppl., 2014, 92: 48-54.
30. Becker MA Schumacher H, Wortmann R et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med, 2005, 353: 2450-2461.
31. Becker M, Schumacher H Jr, Wortmann R et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, phase II, randomized, double-blind, placebocontrolled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum, 2005, 52: 916–923.
32. Schumacher H, Becker M, Wortmann R et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemiaand gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum, 2008, 59: 1540-1548.
33. Love BL, Barrons R, Veverka A, Snider KM. Urate-lowering therapy for gout: Focus on febuxostat. Pharmacotherapy, 2010, 30: 594– 608.
34. Calogiuri G, Nettis E, Di Leo E et al. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets, 2013, 12: 19-28.
35. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol, 2011, 38: 1957-1959.
Review
For citations:
Eliseev MS. PNEUMOCYSTIC PNEUMONIA IN RHEUMATIC DISEASES: CURRENT ISSUES IN PROPHYLAXIS. Meditsinskiy sovet = Medical Council. 2017;(20):144-150. (In Russ.) https://doi.org/10.21518/2079-701X-2017-20-144-150
Views:
1491
Email this article 